CALA - Calithera Biosciences, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
4.4600
-0.1100 (-2.41%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close4.5700
Open4.5900
Bid4.30 x 1000
Ask5.15 x 900
Day's Range4.4400 - 4.6500
52 Week Range3.5500 - 9.3500
Volume127,615
Avg. Volume295,188
Market Cap170.041M
Beta (3Y Monthly)1.99
PE Ratio (TTM)N/A
EPS (TTM)-1.28
Earnings DateNov 7, 2017 - Nov 13, 2017
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est12.25
Trade prices are not sourced from all markets
  • What Did Calithera Biosciences, Inc.’s (NASDAQ:CALA) CEO Take Home Last Year?
    Simply Wall St.3 days ago

    What Did Calithera Biosciences, Inc.’s (NASDAQ:CALA) CEO Take Home Last Year?

    In 2010 Susan Molineaux was appointed CEO of Calithera Biosciences, Inc. (NASDAQ:CALA). This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. After that, Read More...

  • GlobeNewswire14 days ago

    Calithera Biosciences Provides Corporate Updates and Announces Key Executive Promotions to Drive Continued Growth of the Company’s Pipeline

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced several executive promotions. "I am pleased to announce today's promotions which highlight the talent, skill set and extensive achievements of our executive team," said Susan Molineaux, PhD, President and Chief Executive Officer of Calithera. "It is critical that we have the right leadership in place to reach key clinical milestones as we drive CB-839 towards commercialization with two randomized trials of the glutaminase inhibitor CB-839 for the treatment of patients with advanced renal cell carcinoma.

  • GlobeNewswire2 months ago

    Calithera Biosciences to Participate in the 2018 Citi Global Healthcare Conference

    Calithera Biosciences, Inc. (CALA), a clinical stage biotechnology company focused on  discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced its participation at the 2018 Citi Global Healthcare Conference.  Calithera will host meetings with investors at the conference in New York on Thursday, December 6, 2018. Calithera is a clinical-stage biopharmaceutical company focused on fighting cancer by discovering, developing, and commercializing novel small molecule drugs that target tumor and immune cell metabolism.  Calithera is headquartered in South San Francisco, California.  For more information about Calithera, please visit www.calithera.com.

  • Intrinsic Calculation For Calithera Biosciences Inc (NASDAQ:CALA) Shows Investors Are Overpaying
    Simply Wall St.2 months ago

    Intrinsic Calculation For Calithera Biosciences Inc (NASDAQ:CALA) Shows Investors Are Overpaying

    Does the November share price for Calithera Biosciences Inc (NASDAQ:CALA) reflect it’s really worth? Today, I will calculate the stock’s intrinsic value by taking the expected future cash flows and Read More...

  • Thomson Reuters StreetEvents2 months ago

    Edited Transcript of CALA earnings conference call or presentation 7-Nov-18 10:00pm GMT

    Q3 2018 Calithera Biosciences Inc Earnings Call

  • Calithera (CALA) Reports Q3 Loss, Lags Revenue Estimates
    Zacks2 months ago

    Calithera (CALA) Reports Q3 Loss, Lags Revenue Estimates

    Calithera (CALA) delivered earnings and revenue surprises of -26.83% and -100.00%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press2 months ago

    Calithera: 3Q Earnings Snapshot

    On a per-share basis, the South San Francisco, California-based company said it had a loss of 52 cents. The results missed Wall Street expectations. The average estimate of three analysts surveyed by Zacks ...

  • GlobeNewswire2 months ago

    Calithera Biosciences Reports Third Quarter 2018 Financial Results and Recent Highlights

    SOUTH SAN FRANCISCO, Calif., Nov. 07, 2018 -- Calithera Biosciences, Inc. (Nasdaq: CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel.

  • GlobeNewswire3 months ago

    Calithera Biosciences to Report Third Quarter 2018 Financial Results on Wednesday, November 7, 2018

    Calithera Biosciences, Inc. (CALA), a clinical-stage pharmaceutical company focused on discovering and developing novel small molecule drugs directed against tumor metabolism and tumor immunology targets for the treatment of cancer, today announced that the Company’s third quarter 2018 financial results will be released on Wednesday, November 7, 2018. Company management will host a conference call on Wednesday, November 7, 2018 at 2:00 p.m. Pacific Time/ 5:00 p.m. Eastern Time to discuss the financial results and other recent corporate highlights. The press release and live audio webcast can be accessed via the Investor section of the Company’s website at www.calithera.com.

  • Simply Wall St.4 months ago

    What Investors Should Know About Calithera Biosciences Inc’s (NASDAQ:CALA) Financial Strength

    Calithera Biosciences Inc (NASDAQ:CALA), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. However, the trade-off is CALA Read More...

  • Thomson Reuters StreetEvents5 months ago

    Edited Transcript of CALA earnings conference call or presentation 7-Aug-18 9:00pm GMT

    Q2 2018 Calithera Biosciences Inc Earnings Call

  • Calithera (CALA) Reports Q2 Loss, Tops Revenue Estimates
    Zacks5 months ago

    Calithera (CALA) Reports Q2 Loss, Tops Revenue Estimates

    Calithera (CALA) delivered earnings and revenue surprises of 72.73% and 230.40%, respectively, for the quarter ended June 2018. Do the numbers hold clues to what lies ahead for the stock?

  • Associated Press5 months ago

    Calithera: 2Q Earnings Snapshot

    The South San Francisco, California-based company said it had a loss of 9 cents per share. The results exceeded Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment ...

  • ACCESSWIRE5 months ago

    Calithera Biosciences, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Calithera Biosciences, Inc. (NASDAQ: CALA ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 5:00 PM Eastern ...

  • ACCESSWIRE7 months ago

    Complimentary Technical Snapshots on Celgene and Three More Biotech Stocks

    Four stocks have been lined up for today's assessment, and they are: Calithera Biosciences Inc. (CALA), Cara Therapeutics Inc. (CARA), Celgene Corp. (CELG), and Celldex Therapeutics Inc. (CLDX). Shares in South San Francisco, California headquartered Calithera Biosciences Inc. jumped 5.53%, ending Wednesday's trading session at $5.25. The stock recorded a trading volume of 552,298 shares, which was higher than its three months average volume of 426,620 shares.